Nothing Special   »   [go: up one dir, main page]

AU2002221080A1 - Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof - Google Patents

Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof

Info

Publication number
AU2002221080A1
AU2002221080A1 AU2002221080A AU2108002A AU2002221080A1 AU 2002221080 A1 AU2002221080 A1 AU 2002221080A1 AU 2002221080 A AU2002221080 A AU 2002221080A AU 2108002 A AU2108002 A AU 2108002A AU 2002221080 A1 AU2002221080 A1 AU 2002221080A1
Authority
AU
Australia
Prior art keywords
substituents
group optionally
pyridyl groups
thiazole derivatives
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221080A
Inventor
Shohei Hashiguchi
Tomohiro Kaku
Noritaka Kuroda
Masami Kusaka
Yoshi Nara
Akihiro Tasaka
Masuo Yamaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2002221080A1 publication Critical patent/AU2002221080A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: <CHEM> wherein A<1> is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A<2> and A<3> is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A<2> and A<3> is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A<1>, A<2> and A<3> is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.
AU2002221080A 2000-12-08 2001-12-07 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof Abandoned AU2002221080A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000373868 2000-12-08
JP2000-373868 2000-12-08
PCT/JP2001/010723 WO2002046186A1 (en) 2000-12-08 2001-12-07 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof

Publications (1)

Publication Number Publication Date
AU2002221080A1 true AU2002221080A1 (en) 2002-06-18

Family

ID=18843165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221080A Abandoned AU2002221080A1 (en) 2000-12-08 2001-12-07 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof

Country Status (8)

Country Link
US (1) US7067537B2 (en)
EP (1) EP1348706B1 (en)
JP (1) JP2008266349A (en)
AT (1) ATE440096T1 (en)
AU (1) AU2002221080A1 (en)
CA (1) CA2431171A1 (en)
DE (1) DE60139639D1 (en)
WO (1) WO2002046186A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569919T3 (en) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA05002082A (en) * 2002-08-23 2005-06-08 Rigel Pharmaceuticals Inc Pyridyl substituted heterocycles useful for treating or preventing hcv infection.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
EP1620412A2 (en) 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
ES2281801T3 (en) * 2003-05-12 2007-10-01 Pfizer Products Inc. BENZAMIDE INHIBITORS OF THE P2X7 RECEIVER.
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
ATE396718T1 (en) * 2003-12-19 2008-06-15 Rigel Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS (HCV) INFECTION
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
JP2008504363A (en) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Combination therapy using benzamide inhibitor of P2X7 receptor
CN1980902A (en) * 2004-06-29 2007-06-13 辉瑞产品有限公司 Method for preparing 5-'4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h'1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
EP2120580B1 (en) * 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
CL2008003158A1 (en) 2007-10-26 2009-05-29 Univ California Compounds derived from diarylthiohydantoin with strong antagonistic activity and with minimal agonist activity on the androgen receptor (ar); preparation procedure; pharmaceutical composition comprising them; use in the treatment of a proliferative disorder such as prostate cancer.
JP2011513203A (en) * 2008-03-14 2011-04-28 大塚製薬株式会社 MMP-2 and / or MMP-9 inhibitor
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
EA031153B1 (en) 2011-06-10 2018-11-30 Мерк Патент Гмбх Use of pyrimidine compounds with btk inhibitory activity
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
AU2013346882B2 (en) * 2012-11-16 2017-05-04 F. Hoffmann-La Roche Ag Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
WO2019014315A1 (en) * 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
MX2022010693A (en) * 2020-02-28 2022-09-26 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821384A (en) * 1972-10-06 1974-06-28 Uniroyal Inc Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same
US4153703A (en) 1977-06-30 1979-05-08 Uniroyal, Inc. Method of controlling insects and acarids with certain aryl-substituted thiazoles
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
NZ224288A (en) 1987-04-22 1989-12-21 Merrell Dow Pharma 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
DE69227986T2 (en) 1991-03-01 1999-06-17 Electrostatic Technology, Inc., Branford, Conn. POWDER COATING METHOD FOR THE PRODUCTION OF CIRCUIT BOARDS AND SIMILAR
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
EP0721943A4 (en) 1993-09-30 1996-09-04 Yamanouchi Pharma Co Ltd Azole derivative and pharmaceutical composition thereof
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
PL322028A1 (en) 1995-03-01 1998-01-05 Yamanouchi Pharma Co Ltd Derivatives of imidazoles and pharmaceutic composition containing them
WO1997000257A1 (en) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
EP0880540B1 (en) 1996-02-14 2002-06-12 Aventis Pharmaceuticals Inc. 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase
EP0906115A1 (en) * 1996-04-30 1999-04-07 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
AU4298997A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
AU4015497A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
JPH10195056A (en) 1996-11-12 1998-07-28 Takeda Chem Ind Ltd Condensed benzene derivative, its production and agent
TR199902442T2 (en) 1997-01-28 2000-07-21 Merck & Co.,Inc. Thiazole benzenesulfonamides as β3 agonists in the treatment of sugar and obesity.
ATE231128T1 (en) * 1997-02-21 2003-02-15 Takeda Chemical Industries Ltd JOINTS WITH CONDENSED RINGS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION
JPH1179993A (en) * 1997-09-05 1999-03-23 Sumitomo Pharmaceut Co Ltd Immunosuppressant
HUP0004037A3 (en) 1997-10-02 2002-03-28 Daiichi Seiyaku Co Novel dihydronaphthalene compounds and process for producing the same
ATE257703T1 (en) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA, ALLERGIES AND DIABETES
ATE293102T1 (en) * 1998-04-23 2005-04-15 Takeda Pharmaceutical NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE
CA2368122A1 (en) 1999-03-15 2000-09-21 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
JP2000302680A (en) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd Brain protective agent
AU765473B2 (en) 1999-04-23 2003-09-18 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
WO2001010865A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
AU7950100A (en) 1999-10-22 2001-05-08 Takeda Chemical Industries Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
WO2001068645A2 (en) 2000-03-15 2001-09-20 Axys Pharmaceuticals, Inc. N-cyanomethylcarboxamides and their use as protease inhibitors
AU2001248820A1 (en) * 2000-04-28 2001-11-12 Shionogi And Co., Ltd. Thiazole and oxazole derivatives
EP1432698A2 (en) * 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors

Also Published As

Publication number Publication date
ATE440096T1 (en) 2009-09-15
EP1348706A4 (en) 2005-08-10
US7067537B2 (en) 2006-06-27
WO2002046186A1 (en) 2002-06-13
DE60139639D1 (en) 2009-10-01
JP2008266349A (en) 2008-11-06
EP1348706B1 (en) 2009-08-19
EP1348706A1 (en) 2003-10-01
CA2431171A1 (en) 2002-06-13
US20040072876A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AU2002221080A1 (en) Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1467982B8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
NO20073393L (en) [1,2,4] tnazolo [4,3-A] pyridine derivatives for the treatment of hyperproliferative diseases
ATE253545T1 (en) BIARYLACETIC ACID DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS
HU9202265D0 (en) Wall-mounted disc for joining sanitary equipments onto mounting wall
DE60233239D1 (en) benzothiazepine derivatives
PL375513A1 (en) 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
PL369078A1 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
KR960704852A (en) Azole derivatives and pharmaceutical compositions thereof
AU1398697A (en) Intimal hypertrophy inhibitors
PL359415A1 (en) Oxadiazole derivatives having anticancer effects
AU2003223340A1 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
WO2004069139A3 (en) 4-aminopyrimidin-5-yl-methanone derivatives for inhibition of cdk4 activity
EP1227086A4 (en) 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
NO983444L (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 &lt;alfa&gt; reductase inhibitors
DK0982305T3 (en) Indan-1-ol derivatives, process for their preparation and pharmaceutical compositions containing the derivatives
MXPA02011352A (en) Novel benzofuran derivatives.
PL349220A1 (en) Heterocyclic derivatives as inhibitors of factor xa
AU2002214320A1 (en) Imidazole derivatives, process for their preparation and their use
AU3285000A (en) 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
IL149306A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
ES2184633A1 (en) Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives
MX2022015986A (en) Aminopyrimidinyl derivatives.
TW288015B (en) New chromene derivatives